PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know

Key Takeaways PRAX surged on pivotal Essential3 results showing ulixacaltamide met all key endpoints in essential tremor.Efficacy appeared early and was sustained, with Study 2 confirming a maintained response versus placebo.Progress on pre-NDA steps and positive relutrigine data added further fuel to PRAX's recent stock rally.Shares of Praxis Precision Medicines (PRAX) have skyrocketed 519.5% in the past three months. The sharp rally in the stock was largely fueled by encouraging top-line data from two piv ...